Alan Nicholas - Concepedia

Concepedia

Author

Alan Nicholas

The University of Texas MD Anderson Cancer Center

Also Known As

Alan Nicholas, Nicholas, Alan

71

Publications

2.6K

Citations

16

H-Index

47

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center Dana-Farber Cancer Institute Moffitt Cancer Center University of California, Los Angeles City of Hope

AN

About

Alan Nicholas is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, cancer therapeutics, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	1.9K
2	Health Sciences	4	4	136
3	Engineering	1	1	17
4	Biostatistics	1	1	17
5	Emergency Medicine	1	1	37

Alan Nicholas

×

20

Publications

2.6K

Citations

16

H-Index

	Year	Citations
Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma Ann‐Lii Cheng, Shukui Qin, Masafumi Ikeda, Journal of Hepatology HepatologyAtezolizumab Plus BevacizumabUnresectable Hepatocellular CarcinomaMedicineImmunology	2021	1.5K
Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial Jamie E. Chaft, Filiz Öezkan, Mark G. Kris, Nature Medicine	2022	222
Developmental change in the influence of domain-general abilities and domain-specific knowledge on mathematics achievement: An eight-year longitudinal study. David C. Geary, Alan Nicholas, Yaoran Li, Journal of Educational Psychology	2017	176
Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Interim analysis and biomarker data from a multicenter study (LCMC3). David J. Kwiatkowski, Valerie W. Rusch, Jamie E. Chaft, Journal of Clinical Oncology Surgical OncologyImmunologyPathologyImmunotherapeuticsImmunotherapy	2019	146
Pertuzumab Plus High-Dose Trastuzumab in Patients With Progressive Brain Metastases and HER2-Positive Metastatic Breast Cancer: Primary Analysis of a Phase II Study Nancy U. Lin, Mark D. Pegram, Solmaz Sahebjam, Journal of Clinical Oncology	2021	92
Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM) Herbert I. Hurwitz, Benjamin Tan, James A. Reeves, The Oncologist	2018	89
IMbrave150: Exploratory efficacy and safety results of hepatocellular carcinoma (HCC) patients (pts) with main trunk and/or contralateral portal vein invasion (Vp4) treated with atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in a global Ph III study. Arndt Vogel, Philippe Merle, Richard S. Finn, Journal of Clinical Oncology Portal Vein PressurePathologyMultimodalityPharmacotherapyTumor Thrombus	2021	68
Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Initial results from a multicenter study (LCMC3). Valerie W. Rusch, Jamie E. Chaft, Bruce E. Johnson, Journal of Clinical Oncology Surgical OncologyCancer ManagementImmunologyPathologyImmunotherapeutics	2018	54
IMbrave150: Exploratory analysis to examine the association between treatment response and overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor). Michel Ducreux, Andrew X. Zhu, Ann‐Lii Cheng, Journal of Clinical Oncology Clinical EndpointClinical SpecialtiesPathologyPharmacotherapyOverall Survival	2021	37
Atezolizumab plus Bevacizumab versus Sorafenib for Unresectable Hepatocellular Carcinoma: Results from Older Adults Enrolled in the IMbrave150 Randomized Clinical Trial Daneng Li, Han Chong Toh, Philippe Merle, Liver Cancer	2022	34

Page 1